Navigation Links
Mesothelin engineered on virus-like particles provides treatment clues for pancreatic cancer
Date:2/14/2008

New understanding of a protein that spurs the growth of pancreatic cancer could lead to a new vaccine against the deadly disease, said researchers at Baylor College of Medicine in Houston in a report appearing in the current edition of the journal Molecular Cancer Therapeutics.

The protein called mesothelin appears to play an important role in promoting pancreatic cancer growth, said the senior author Dr. Qizhi (Cathy) Yao, professor of surgery vascular surgery at BCM. She, along with co-lead authors Dr. Min Li, assistant professor of surgery, and research associate Dr. Uddalak Bharadwaj carried out the studies of the protein that is found on the tumor cells surface.

Mesothelin is found in other cancers for several years, said Yao, also a researcher in the Dan L. Duncan Cancer Center at BCM. However, we didnt know the role it played in pancreatic cancer: until she and her colleagues reported in this article. In fact, they found very high levels of mesothelin in 18 of 21 samples of patients pancreatic tissues compared to amounts found in nearby normal tissues. In studies of this protein in the lab, pancreatic cancer cell lines that produced high levels of mesothelin grew faster and spread more than those in which mesothelin levels were lower.

Pancreatic cancer cells grew and spread faster in mice whose tumors expressed high levels of mesothelin than in those whose cancer did not, said the researchers, who conducted the studies in an immune deficient mouse.

We saw this molecule as very significant in the life of the tumor cells, Yao said. Our next step is to identify whether this would be a good active immunotherapy target.

Making a treatment vaccine of virus-like particles (VLPs) that contained mesothelin, researchers injected mice having pancreatic cancer with this vaccine three times. Virus-like particles have the unique property of inducing protective immune responses but they lack the infectious capacities of the original virus.

Tumor growth in the immunized mice slowed and in some cases the tumor disappeared. The average life span for the mice not treated was four weeks. The immunized mice survived five weeks longer than those not treated.

Researchers found that the immunization works by suppressing production of key immune system cells that suppress the bodys ability to fight the tumor. The researchers said pancreatic cancers produce these cells, called T regulatory cells, as a protective measure.

If we are able to see the same results in humans, this would allow us to incorporate a combination therapy to treat the tumor, Yao said. Treatment with a single drug is not effective.

Yao and her colleagues are seeking U.S. Food and Drug Administration approval to begin studies using their vaccination on people suffering from pancreatic cancer.


'/>"/>

Contact: Graciela Gutierrez
ggutierr@bcm.edu
713-798-4710
Baylor College of Medicine
Source:Eurekalert

Related biology news :

1. MIT works toward engineered blood vessels
2. Engineered weathering process could mitigate global warming
3. Genetically engineered corn may harm stream ecosystems
4. Study shows genetically engineered corn could affect aquatic ecosystems
5. Engineered eggshells to help make hydrogen fuel
6. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
7. A step toward tissue-engineered heart structures for children
8. Tiny dust particles from Asian deserts common over western United States
9. MIT sculpts 3-D particles with light
10. MIT: Remote-control nanoparticles deliver drugs directly into tumors
11. Worldwide atmospheric measurements will determine the role of atmospheric fine particles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... 2017  Hunova, the first robotic gym for the rehabilitation and functional ... in Genoa, Italy . The first 30 robots will ... USA . The technology was developed and patented at ... IIT spin-off Movendo Technology thanks to a 10 million euro investment from ... click: ...
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... N.C. (PRWEB) , ... October 09, 2017 , ... At ... announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, ... Stubbs was a member of the winning team for the 2015 Breakthrough Prize in ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
Breaking Biology Technology: